- Home
- PYXS vs PRLD Comparison
PYXS vs PRLD Comparison
Compare PYXS & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PYXS | PRLD |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 69.1M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PYXS | PRLD |
|---|---|---|
| Price | $1.78 | $1.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $6.75 | $4.00 |
| AVG Volume (30 Days) | ★ 2.6M | 560.6K |
| Earning Date | 11-03-2025 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,820,000.00 | ★ $10,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 250.00 |
| 52 Week Low | $0.83 | $0.61 |
| 52 Week High | $5.55 | $4.22 |
Technical Indicators
Market Signals| Indicator | PYXS | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 41.92 | 40.85 |
| Support Level | $1.03 | $2.05 |
| Resistance Level | $2.17 | $2.30 |
| Average True Range (ATR) | 0.20 | 0.31 |
| MACD | 0.16 | -0.11 |
| Stochastic Oscillator | 66.22 | 5.57 |
Price Performance
Historical ComparisonAbout PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.